GlassScriptPhysician profile
Hameed Ali
NPI 1104974955
$773,236.82
in general payments reported to CMS, 2019-2025
37 companies · $48K in 2025
The $48K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185K · 2020: $111K · 2021: $139K · 2022: $152K · 2023: $82K · 2024: $55K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $140K · Travel and Lodging: $33K · Food and Beverage: $9,079 · Consulting Fee: $3,065 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $139,779.00 |
| Travel and Lodging | $33,355.96 |
| Food and Beverage | $9,078.66 |
| Consulting Fee | $3,065.00 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $268,141.10 | 2019-2024 | Xarelto |
| Paratek Pharmaceuticals, INC. | $197,840.02 | 2019-2025 | Nuzyra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $75,461.36 | 2019-2025 | Lifevest |
| Alexion Pharmaceuticals, INC. | $73,714.97 | 2019-2024 | Ultomiris |
| Allergan, INC. | $33,565.35 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $28,279.05 | 2019-2024 | |
| Abbvie INC. | $20,507.17 | 2021-2025 | Dalvance, Teflaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19,711.07 | 2019-2023 | Xifaxan |
| Portola Pharmaceuticals, LLC | $14,916.56 | 2019-2020 | |
| Pfizer INC. | $12,206.94 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $9,022.77 | 2019-2023 | Lokelma, Brilinta, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $8,282.80 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $3,520.27 | 2019-2024 | Recarbrio, Dificid, Zerbaxa |
| Melinta Therapeutics, LLC | $2,445.32 | 2019-2022 | |
| Vifor Pharma, INC. | $1,295.42 | 2020-2024 | Veltassa, Korsuva |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $1,291.53 | 2020-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Altathera Pharmaceuticals LLC | $500.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $452.73 | 2019-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $271.20 | 2023 | Lupkynis |
| Ferring Pharmaceuticals INC. | $226.41 | 2022-2024 | Rebyota |
| Astellas Pharma US INC | $212.88 | 2020-2024 | |
| Novo Nordisk INC | $194.36 | 2019-2022 | |
| Abbott Laboratories | $159.60 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $142.63 | 2021-2023 | Xarelto |
| Shionogi INC | $132.77 | 2021-2025 | Fetroja |
| Esperion Therapeutics, INC. | $118.18 | 2020-2024 | Nexletol |
| Mallinckrodt Hospital Products INC. | $101.79 | 2024 | Terlivaz |
| Grt US Holding, INC. | $100.00 | 2021 | |
| Pharmacosmos Therapeutics INC. | $92.96 | 2020-2021 | |
| Dexcom, INC. | $87.83 | 2023-2025 | Dexcom G6 Transmitter |
| Chiesi USA, INC. | $65.52 | 2020-2022 | |
| Biogen, INC. | $43.69 | 2021 | |
| Bioxcel Therapeutics, INC. | $42.78 | 2023 | Igalmi |
| Boston Scientific Corporation | $34.30 | 2024 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $25.83 | 2022 | |
| Fisher & Paykel Healthcare INC | $17.82 | 2023 | Fisher & Paykel Healthcare |
| Smith+Nephew, INC. | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hameed Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.